• About Us
    • Our Company
    • Management & Board
  • Aceragen
  • Tilsotolimod
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Investor Relations
×

Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy